scholarly journals Undifferentiated carcinoma of the liver in a 3-year-old girl treated by neoadjuvant chemotherapy and complete resection

2021 ◽  
Vol 78 ◽  
pp. 67-70
Author(s):  
Takanori Ochi ◽  
Junya Fujimura ◽  
Atsushi Arakawa ◽  
Geoffrey J. Lane ◽  
Atsuyuki Yamataka ◽  
...  
Keyword(s):  
Neoadjuvant Chemotherapy ◽  
Undifferentiated Carcinoma ◽  
Complete Resection

TRUST: Trial of Radical Upfront Surgical Therapy in advanced ovarian cancer (ENGOT ov33/AGO‐OVAR OP7)

2019 ◽  
Vol 29 (8) ◽  
pp. 1327-1331 ◽  
Author(s):  
Alexander Reuss ◽  
Andreas du Bois ◽  
Philipp Harter ◽  
Christina Fotopoulou ◽  
Jalid Sehouli ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Overall Survival ◽  
Neoadjuvant Chemotherapy ◽  
Cytoreductive Surgery ◽  
Advanced Ovarian Cancer ◽  
Figo Stage ◽  
Complete Resection ◽  
Peritoneal Carcinoma ◽  
Exclusion Criteria ◽  
Platinum Based Chemotherapy

BackgroundPrimary cytoreductive surgery followed by chemotherapy has been considered standard management for patients with advanced ovarian cancer over decades. An alternative approach of interval debulking surgery following neoadjuvant chemotherapy was subsequently reported by two randomized phase III trials (EORTC‐GCG, CHORUS), which were criticized owing to important limitations, especially regarding the rate of complete resection.Primary ObjectiveTo clarify the optimal timing of surgical therapy in advanced ovarian cancer.Study HypothesisPrimary cytoreductive surgery is superior to interval cytoreductive surgery following neoadjuvant chemotherapy for overall survival in patients with advanced ovarian cancer.Trial DesignTRUST is an international open, randomized, controlled multi-center trial investigating overall survival after primary cytoreductive surgery versus neoadjuvant chemotherapy and subsequent interval cytoreductive surgery in patients with FIGO stage IIIB–IVB ovarian, tubal, and peritoneal carcinoma. To guarantee adequate surgical quality, participating centers need to fulfill specific quality assurance criteria (eg, ≥50% complete resection rate in upfront surgery for FIGO IIIB–IVB patients, ≥36 debulking-surgeries/year) and agree to independent audits by TRUST quality committee delegates. Patients in the primary cytoreductive surgery arm undergo surgery followed by 6 cycles of platinum-based chemotherapy, whereas patients in the interval cytoreductive surgery arm undergo 3 cycles of neoadjuvant chemotherapy after histologic confirmation of the disease, followed by interval cytoreductive surgery and subsequently, 3 cycles of platinum-based chemotherapy. The intention of surgery for both groups is complete tumor resection according to guideline recommendations.Major Inclusion/Exclusion CriteriaMajor inclusion criteria are suspected or histologically confirmed, newly diagnosed invasive epithelial ovarian cancer, fallopian tube carcinoma, or primary peritoneal carcinoma FIGO stage IIIB–IVB (IV only if resectable metastasis). Major exclusion criteria are non-epithelial ovarian malignancies and borderline tumors; prior chemotherapy for ovarian cancer; or abdominal/pelvic radiotherapy.Primary EndpointOverall survival.Sample Size772 patients.Estimated Dates for Completing Accrual and Presenting ResultsAccrual completion approximately mid-2019, results are expected after 5 years' follow-up in 2024.Trial RegistrationNCT02828618.

Comparison of radical surgery followed by adjuvant chemotherapy with radical surgery following neoadjuvant chemotherapy as initial treatment for patients with locally advanced thoracic esophageal squamous cell carcinoma.

2015 ◽  
Vol 33 (3_suppl) ◽  
pp. 187-187
Author(s):  
Yasuhiro Tsubosa ◽  
Masahiro Niihara ◽  
Satoru Matsuda ◽  
Katsuhisa Ogi ◽  
Katsushi Takebayashi ◽  
...  
Keyword(s):  
Squamous Cell Carcinoma ◽  
Adjuvant Chemotherapy ◽  
Neoadjuvant Chemotherapy ◽  
Radical Surgery ◽  
Locally Advanced ◽  
Complete Resection ◽  
Resection Rate ◽  
Complete Resection Rate ◽  
Significant Difference ◽  
Treat Analysis

187 Background: Although radical surgery with neoadjuvant chemotherapy (NAC) is a standard therapy for locally advanced thoracic esophageal squamous cell carcinoma (ESCC) in response to the result of JCOG 9907 study in Japan, there was no significant difference in survival rate at adjuvant chemotherapy and neoadjuvant chemotherapy in cStage III at subanalysis. Methods: Consecutive patients histologically diagnosed with ESCC and planned to undergo radical surgery followed by adjuvant chemotherapy (ADJ) from September 2002 to April 2007 and radical surgery following NAC from May 2007 to December 2011 as initial treatment were eligible for this retrospective study. To select patients who could tolerate transthoracic esophagectomy, respiratory function, Eastern Cooperative Oncology Group performance status, and preoperative complications were considered. As adjuvant and neoadjuvant chemotherapy, cisplatin and 5-fluorouracil were administered every 3 weeks for 2 cycles (FP). Patient characteristics, 3-year overall survival (3yOS) and non complete resection rate were investigated. We analyzed in intent-to-treat analysis. Results: Ninety patients were included in ADJ group, 98 included in NAC group. No significant differences were observed in clinicopathological factors between ADJ group (cStage IB/II/III/IV=6/22/57/5) and NAC group (cStage IB/II/III/IV=10/28/52/8). In intention-to-treat analysis, there was no significant difference in 3yOS rate by ADJ group and NAC group (ADJ group, 67.2%; NAC group, 66.0%; p = 0.301). However, non complete resection rate was significantly higher for NAC group than for ADJ group {ADJ group, 16.7% (3/90); NAC group, 3.4% (14/98); p = 0.009}. In cStage III, non complete resection rate of ADJ group was 3.5% (2/57) and NAC group was 25% (13/52). In the patients with cStage III, NAC group had a tendency for 3yOS rate to be low rather than ADJ group (ADJ group, 66.3%; NAC group, 51.1%; p = 0.09). Conclusions: In cStage III advanced ESCC, FP as NAC may be insufficient and development of the more powerful NAC is desired.

scholarly journals Complete resection of a huge pancreatic undifferentiated carcinoma with osteoclast-like giant cells

2017 ◽  
Vol 6 (4) ◽  
pp. 193-196 ◽  
Author(s):  
Tomohiro Yazawa ◽  
Akira Watanabe ◽  
Kenichiro Araki ◽  
Atsuki Segawa ◽  
Keitaro Hirai ◽  
...  
Keyword(s):  
Giant Cells ◽  
Undifferentiated Carcinoma ◽  
Complete Resection

scholarly journals Thymic Squamous Cell Carcinoma: A Population-Based Surveillance, Epidemiology, and End Result Analysis

2020 ◽  
Vol 10 ◽  
Author(s):  
Xudong Yang ◽  
Kejia Zhao ◽  
Chuan Li ◽  
Yanbo Yang ◽  
Chenglin Guo ◽  
...  
Keyword(s):  
Squamous Cell Carcinoma ◽  
Cell Carcinoma ◽  
Squamous Cell ◽  
Protective Factor ◽  
Strong Association ◽  
Univariate Analysis ◽  
Undifferentiated Carcinoma ◽  
Complete Resection ◽  
Incomplete Resection ◽  
Thymic Carcinomas

ObjectivesThymic squamous cell carcinoma (TSCC) is a rare neoplasm that has been sparsely cited in the literature. The aim of this study was to determine disease characteristics and prognostic factors of patients in a Surveillance, Epidemiology, and End Results (SEER) analysis.MethodsCases from 1990–2016 were retrieved from the SEER database and demographics, treatments, and survival outcomes were analyzed.ResultsThe TSCC accounted for 72.4% of the thymic carcinomas and 7.2% of thymic tumors. The 276 patients (165 men) selected for analysis had a median age of 65 (24–85) years, and 201 patients were diagnosed with Masaoka-Koga stage III/IV. The median survival of TSCC was 59 months with a 49.0% 5-year OS rate, a better prognosis than lymphoepithelioma-like carcinoma (32.1%) and undifferentiated carcinoma (33.3%). Multivariate analysis revealed the Masaoka-Koga stage (p = 0.003) and surgical types (complete resection, incomplete resection, and none; p < 0.001) were determinants of survival. Complete resection had the best prognosis with a 72.7% 5-year OS rate. Chemotherapy was an independent protective factor (HR = 0.555, 95% CI 0.347–0.886; p = 0.014) though poor survival was showed in univariate analysis. And the survival benefit of chemotherapy was validated in PSM analysis (3-year OS rate was 77.7% with chemotherapy vs. 52.8% without chemotherapy; p = 0.014).ConclusionsTSCC was frequently diagnosed in older patients with advanced Masaoka-Koga stage and had more favorable survival than other subtypes of thymic carcinomas. Complete resection is the preferred treatment. Masaoka-Koga stage and chemotherapy had a strong association with prognosis.

Neoadjuvant paclitaxel plus carboplatin followed by concomitant radiochemotherapy in stage IVb nasopharyngeal carcinoma: Preliminary results

2006 ◽  
Vol 24 (18_suppl) ◽  
pp. 15521-15521
Author(s):  
H. Jouhadi ◽  
N. Tawfiq ◽  
S. Sahraoui ◽  
A. Benider
Keyword(s):  
Neoadjuvant Chemotherapy ◽  
Local Control ◽  
Distant Metastasis ◽  
Nasopharyngeal Cancer ◽  
Undifferentiated Carcinoma ◽  
High Rate ◽  
Weekly Schedule ◽  
Eligibility Criteria ◽  
Concomitant Radiochemotherapy ◽  
Stage Ivb

15521 Background: Nasopharyngeal cancer Is the first head and neck cancer in Morocco. undifferentiated carcinoma (WHO 3)is dominant. Loco regional advanced stages IVa and IVb (AJCC/UICC 1997) represents 60 to 78%. Classical treatment is neoadjuvant chemotherapy (3 courses of BEP protocol) followed by radiotherapy. Therapeutic results are characterised by a high rate of failure. For stage IVb failure is due to distant metastasis wich occur in 30 to 40% of cases needing more systemic therapy. The aim of this prospective study is to analyse for stage IVb the benefit of introducing paclitaxel associated to carboplatin as a neoadjuvante chemotherapy followed by chemoradiation in terms of reducing distant metastasis and improving local control. Tolerance of this protocol was also analysed. Methods: Between September 2003 and January 2004, a total of 33 previously untreated, histologically confirmed NPC adults, were enrolled in this study. The new protocol is based on 1-Four courses of neoadjuvant chemotherapy (1 course = paclitaxel: 175 mg/m2 day 1 + carboplatin: 300 mg/m2 day 1; 1 course every 21 days) 2-followed by a concomitant radiochemotherapy: -radiotherapy to a total dose of 65 gray -and low dose of cisplatine (30 mg/m2) delivered on a weekly schedule. Eligibility criteria were: histologically confirmed NPC, stage IVb, no prior treatment, and informed consent of patients. There were 21 male and 12 female patients and their ages ranged from 19 to 58 years. Results: The minimal follow up was 2 years. The 2 year DFS was 85% and the 2 year loco regional free survival was 91%. All patients completed radiotherapy. Neutropenia grade III-IV was observed in 6% without fever. According to NCI toxicity criteria, acute mucositis (due to radiation) grade 3 was observed in 15% and grade 2 in 24%. Xerostomia grade 1 was observed in 70%. Conclusion: This protocol is very effective with less toxicity. Radiation dose is reduced without decreasing local control rate. The 2 years DFS is increased with this protocol to 85%. No significant financial relationships to disclose.

Neoadjuvant chemotherapy followed by radiotherapy or chemoradiation for locally advanced nasal and paranasal sinus tumors

2009 ◽  
Vol 27 (15_suppl) ◽  
pp. 6055-6055
Author(s):  
S. Hameed ◽  
A. Jamshed ◽  
R. Hussain ◽  
M. Ali ◽  
H. Iqbal ◽  
...  
Keyword(s):  
Neoadjuvant Chemotherapy ◽  
Paranasal Sinus ◽  
Maxillary Antrum ◽  
Locally Advanced ◽  
Survival Rates ◽  
Undifferentiated Carcinoma ◽  
Histopathological Diagnosis ◽  
Complete Regression ◽  
Radiotherapy Dose ◽  
Disease Free

6055 Background: The treatment of locally advanced nasal and paranasal sinus tumors is controversial. The disease is chemosensitive and there is increasing interest in the use of chemotherapy with radiation in this group of patients. Our aim was to determine survival in patients with locally advanced nasal and paranasal sinus tumors treated with neoadjuvant chemotherapy followed by radiotherapy or chemoradiation (RT/CRT). Methods: Between August 2005 and August 2008, 21 patients with AJCC stage III or IV nasal and paranasal sinus tumors were treated with neoadjuvant chemotherapy followed by RT/CRT in our institution. There were 15 males and 6 females (M 71%:F 29%) with a median age of 49 years (range 19 - 70 years). Site of disease was nasal cavity 33% (7), ethamoid sinus 43% (9), maxillary antrum 19% (4), and frontal sinus in 5% (1) of patients. Histopathological diagnosis was squamous cell carcinoma 43% (9), undifferentiated carcinoma 29% (6), adenocarcinoma 19% (4), esthesioneuroblastoma in 9% (2) of patients. Induction chemotherapy consisted of cisplatin 75 mg / metre2 day 1 and gemcitabine 1 gm / metre2 day 1 and 8 every three weeks. Eighty-five percent (18/21) received 2 cycles of neoadjuvant chemotherapy (range 1–4 cycles) prior to radiotherapy. Radiotherapy dose was 54 Gy - 70 Gy (median radiation dose 66 Gy). Fifty-seven percent (12/21) received concomitant cisplatin with radiotherapy. Results: Response to neoadjuvant chemotherapy; complete in 19% (4), partial in 67% (14), no response/progression 14% (3). Following RT/CRT 86% (18/21) had complete regression of disease. Thirty-three percent (7/21) have failed treatment (local 3, regional 2, and distant metastasis in 2 patients). Among treatment failures 2 patients were successfully salvaged; surgery for local recurrence in one patient and in the other case radiation was given for regional recurrence. Disease free and overall survival at 40 months was 52% and 63%, respectively. Conclusions: Gemcitabine cisplatin chemotherapy has good activity in nasal and paranasal sinus tumors. In combination with RT/CRT survival rates are encouraging and the approach merits further investigations in clinical trials. No significant financial relationships to disclose.

scholarly journals Primary monophasic synovial sarcoma of the pleura: Neoadjuvant chemotherapy followed by complete resection

2010 ◽  
Vol 1 (3) ◽  
pp. 95-101 ◽  
Author(s):  
Ramiro G.M. Silva ◽  
Jefferson L. Gross ◽  
Rodrigo A. Silva ◽  
Fabio J. Haddad ◽  
Riad N. Younes ◽  
...  
Keyword(s):  
Neoadjuvant Chemotherapy ◽  
Synovial Sarcoma ◽  
Complete Resection

scholarly journals Complete resection of a primitive neuroectodermal tumour arising in the bladder of a 31-year-old female after neoadjuvant chemotherapy

2016 ◽  
Vol 10 (7-8) ◽  
pp. 264 ◽  
Author(s):  
Cameron J. Lam ◽  
Bobby Shayegan
Keyword(s):  
In Situ Hybridization ◽  
Neoadjuvant Chemotherapy ◽  
Urinary Bladder ◽  
Fluorescent In Situ Hybridization ◽  
Complete Resection ◽  
Chromosomal Translocations ◽  
Rare Occurrence ◽  
Gross Hematuria ◽  
Primitive Neuroectodermal Tumour

Primitive neuroectodermal tumours (PNET) that arise in the urinary bladder are an extremely rare occurrence. Very few cases have been reported so far in the literature1-13 and we report another case here in a 31-year-old-female. The patient presented with polyuria, gross hematuria, followed by development of anuria, and was discovered to have a 9.4 cm mass arising in the posterolateral aspect of the bladder. Histologically, the tumour showed small, round, blue cells. Further analysis using break-apart fluorescent in situ hybridization (FISH) revealed non-random chromosomal translocations of the ews gene suggestive of Ewing sarcoma (ES)/ PNET. The patient completed seven cycles of neoadjuvant chemotherapy, which significantly reduced the size of the lesion. Due to the location of the lesion, surgical resection of the entire bladder and urethra with use of a continent cutaneous reservoir was performed. Here, the management of a 31-year-old female with ES/ PNET arising from the bladder is reported.

Sign in / Sign up

Export Citation Format

Share Document